Antigen-specific active immunotherapy for ovarian cancer

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Ovarian cancer prognosis remains poor despite chemotherapy advancements.
• Antigen-specific active immunotherapy offers a potential alternative treatment by stimulating anti-tumour immune responses.

Purpose of the Study:

• To evaluate the feasibility of antigen-specific active immunotherapy for ovarian cancer.
• Primary outcomes include clinical efficacy and antigen-specific immunogenicity.
• Secondary outcomes assess carrier-specific immunogenicity and side effects.

Main Methods:

• Systematic search of multiple databases (CENTRAL, MEDLINE, EMBASE) and clinicaltrials.gov from 1966 to July 2009.
• Included randomized controlled trials (RCTs) and non-randomized non-controlled studies of ovarian cancer patients treated with antigen-specific active immunotherapy.
• Data extraction and risk of bias assessment performed independently by two reviewers.

Main Results:

• Thirty-six studies were included, but response definitions varied, hindering result comparison.
• CA-125 targeted antibody therapy showed no clinical benefit in three large RCTs, despite inducing immune responses in 60% of patients.
• Other antigen-targeted therapies showed promising immunological results but require further RCT validation.

Conclusions:

• Currently, no clinically effective antigen-specific active immunotherapy is available for ovarian cancer, despite encouraging immunological findings.
• Standardized guidelines for trial conduct, response definitions, and reporting are crucial for improving immunotherapy trial quality and comparability.